Table 2: The disease indicators of subjects (mean (SD)).

RASLET1DT1DNT2DT2DNHTNHT

RF (U/mL)control7.6 (5.2)5.8 (3.5)6.9 (4.3)7.2 (4.3)7.5 (3.4)8.1 (3.9)7.7 (3.1)6.7 (4.1)
patients 108.4* (51.9)63.8* (7.9)11.4 (5.6)12.3* (5.3)9.1 (4.8)10.5* (6.7)8.2 (4.1)7.5 (3.2)
positive83.2%50.3%3.9%5.1%6.4%5.8%2.8%2.1%

ASO (IU/mL)control133.1 (23.2)118.5 (31.4)115.8 (21.7)113.6 (35.7)129.5 (41.5)123.4 (43.7)141.3 (32.4)135.4 (39.8)
patients 151.6* (45.5)135.4* (42.3)125.6 (33.9)154.2* (36.8)123.8 (41.6)139.8 (37.9)133.1 (45.8)128.3 (21.5)
positive7.8%6.5%6.3%7.2%4.1%5.9%3.8%2.2%

Anti-CCP (U/mL)control2.6 (0.7)3.1 (0.8)NDNDNDNDNDND
patients 63.7 (33.5)17.0 (5.9)NDNDNDNDNDND
positive61.2%11.2%NDNDNDNDNDND

ESR, (mm/h)controlNDNDNDNDNDNDNDND
patients 41 (15)37 (9)18 (7)17 (9)15 (6)19 (5)11 (3)11 (4)
elevated79.2% 65.1% 5.5%3.5%1.7%2.4%1.3%1.9%

hsCRP (mg/L)control1.8 (0.7)2.1 (0.9)2.3 (0.7)1.8 (0.5)2.4 (0.5)3.2 (1.2)2.9 (1.3)2.8 (2.1)
patients 12.8* (5.7)16.5* (8.2)3.1 (1.2)6.3* (0.8)2.3 (0.8)3.7 (1.5)4.4 (1.5)5.1 (1.9)
elevated35.8%42.5%3.9%4.8%5.1%5.5%7.8%6.7%

*There were significant differences between patients and control (P < 0.05).
There were significant differences between T1D, T1DN, T2D, T2DN, HTN, and HT groups.
HTN: hypertensive nephropathy; HT: heart failure; ND: not determined.